We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita Healthcare Partners' New Facility Now in Los Angeles
Read MoreHide Full Article
HealthCare Partners, an important division of DaVita Inc. (DVA - Free Report) recently announced the opening of a new medical facility and urgent care clinic in Los Angeles at Washington Boulevard and Hoover Street. The development has been described as one of the largest health care projects in the city.
The facility has many patient care operations like On-site radiology and lab services, Pain management, Dermatology, Pulmonology, Podiatry, Opthalmology/Optometry, Rheumatology and many more. Further, apart from providing valuable medical services to the Pico Union/University Park communities, the facility is expected to create more employment and increase economic activity.
DaVita’s consistent efforts to upgrade services, global expansion initiatives and active acquisitions are impressive and supported by the company’s strong financial position. The development is likely to strengthen the company’s DaVita Medical Group (“DMG”) segment. For investors’ notice, DMG is on track for divestment to Optum, a subsidiary of UnitedHealth Group Inc.
A Sneak Peek at DMG Performance
DMG, the nation's largest operator of medical groups and physician networks, provides integrated care management.
In the last reported quarter, DaVita announced the restructuring of the DMG segment that eliminated 350 non-clinical positions. Thus, management expects annualized savings of around $40 million per year, starting 2018.
Price Performance
Shares of DaVita have marginally underperformed the industry in a year's time. The stock has gained 27.5% compared with the industry's rally of 28.2%. The current return is also higher than S&P 500’s rise of 17.3%.
DaVita has a Zacks Rank #3 (Hold).
DaVita Grows Internationally as Well!
Apart from fortifying its foothold in the domestic space, DaVita is steadily expanding in the international markets.
In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
These are expected to help DaVita deliver more efficient patient care. Currently, DaVita is planning to expand in major European and Asian countries via acquisitions and partnerships.
By the end of the second quarter of 2018, DaVita’s adjusted operating income for International business was $3 million, which included a $5-million foreign exchange gain from the cash balance in Asia-Pacific joint venture. The company continues to expect breakeven adjusted operating income in late 2018 excluding any foreign exchange gains or losses.
Inogen has a long-term expected earnings growth rate of 22.5%, while the same for Integer Holdings and Patterson Companies is at 15% and 8.3%, respectively.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
DaVita Healthcare Partners' New Facility Now in Los Angeles
HealthCare Partners, an important division of DaVita Inc. (DVA - Free Report) recently announced the opening of a new medical facility and urgent care clinic in Los Angeles at Washington Boulevard and Hoover Street. The development has been described as one of the largest health care projects in the city.
The facility has many patient care operations like On-site radiology and lab services, Pain management, Dermatology, Pulmonology, Podiatry, Opthalmology/Optometry, Rheumatology and many more. Further, apart from providing valuable medical services to the Pico Union/University Park communities, the facility is expected to create more employment and increase economic activity.
DaVita’s consistent efforts to upgrade services, global expansion initiatives and active acquisitions are impressive and supported by the company’s strong financial position. The development is likely to strengthen the company’s DaVita Medical Group (“DMG”) segment. For investors’ notice, DMG is on track for divestment to Optum, a subsidiary of UnitedHealth Group Inc.
A Sneak Peek at DMG Performance
DMG, the nation's largest operator of medical groups and physician networks, provides integrated care management.
In the last reported quarter, DaVita announced the restructuring of the DMG segment that eliminated 350 non-clinical positions. Thus, management expects annualized savings of around $40 million per year, starting 2018.
Price Performance
Shares of DaVita have marginally underperformed the industry in a year's time. The stock has gained 27.5% compared with the industry's rally of 28.2%. The current return is also higher than S&P 500’s rise of 17.3%.
DaVita has a Zacks Rank #3 (Hold).
DaVita Grows Internationally as Well!
Apart from fortifying its foothold in the domestic space, DaVita is steadily expanding in the international markets.
In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
These are expected to help DaVita deliver more efficient patient care. Currently, DaVita is planning to expand in major European and Asian countries via acquisitions and partnerships.
By the end of the second quarter of 2018, DaVita’s adjusted operating income for International business was $3 million, which included a $5-million foreign exchange gain from the cash balance in Asia-Pacific joint venture. The company continues to expect breakeven adjusted operating income in late 2018 excluding any foreign exchange gains or losses.
Want More from the MedTech Space?
A few better-ranked stocks in the MedTech space are Inogen Inc (INGN - Free Report) , Integer Holdings Corp. (ITGR - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) . Inogen and Patterson Companies have a Zacks Rank #2 (Buy). Integer sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 22.5%, while the same for Integer Holdings and Patterson Companies is at 15% and 8.3%, respectively.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>